Elizabeth A. McAninch

Elizabeth A. McAninch

Auto-generated profile, based on publicly available information

Elizabeth A. McAninch

Division of Endocrinology and Metabolism, Rush University Medical Center, Chicago, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2014 in Annals of the New York Academy of Sciences
Verified
Journal Article
Open access
PDF file
EMElizabeth A. McAninch
Elizabeth A. McAninch
ABAntonio C. Bianco
Antonio C. Bianco
The thyroid hormone (TH) plays a significant role in diverse processes related to growth, development, differentiation, and metabolism. TH signaling modulates energy expenditure through both central and peripheral pathways. At the cellular level, the TH exerts its effects after concerted mechanisms facilitate binding to the TH receptor. In the hypothalamus, signals from a range of metabolic pathways, including appetite, temperature, afferent stimuli via the autonomic nervous system, availability of energy substrates, hormones, and other biologically active molecules, converge to maintain plasma TH at the appropriate level to preserve energy homeostasis. At the tissue level, TH actions on metabolism are controlled by transmembrane transporters, deiodinases, and TH receptors. In the modern environment, humans are susceptible to an energy surplus, which has resulted in an obesity epidemic and, thus, understanding the contribution of the TH to cellular and organism metabolism is increasingly relevant.

2 January 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JCJoao Pedro Werneck de Castro
Joao Pedro Werneck de Castro
TFTatiana L. Fonseca
Tatiana L. Fonseca
CUCintia B. Ueta
Cintia B. Ueta
EMElizabeth A. McAninch
Elizabeth A. McAninch
SASherine Abdalla
Sherine Abdalla
ABAntonio C. Bianco
Antonio C. Bianco
The current treatment for patients with hypothyroidism is levothyroxine (L-T4) along with normalization of serum thyroid-stimulating hormone (TSH). However, normalization of serum TSH with L-T4 monotherapy results in relatively low serum 3,5,3′-triiodothyronine (T3) and high serum thyroxine/T3 (T4/T3) ratio. In the hypothalamus-pituitary dyad as well as the rest of the brain, the majority of T3 present is generated locally by T4 deiodination via the type 2 deiodinase (D2); this pathway is self-limited by ubiquitination of D2 by the ubiquitin ligase WSB-1. Here, we determined that tissue-specific differences in D2 ubiquitination account for the high T4/T3 serum ratio in adult thyroidectomized (Tx) rats chronically implanted with subcutaneous L-T4 pellets. While L-T4 administration decreased whole-body D2-dependent T4 conversion to T3, D2 activity in the hypothalamus was only minimally affected by L-T4. In vivo studies in mice harboring an astrocyte-specific Wsb1 deletion as well as in vitro analysis of D2 ubiquitination driven by different tissue extracts indicated that D2 ubiquitination in the hypothalamus is relatively less. As a result, in contrast to other D2-expressing tissues, the hypothalamus is wired to have increased sensitivity to T4. These studies reveal that tissue-specific differences in D2 ubiquitination are an inherent property of the TRH/TSH feedback mechanism and indicate that only constant delivery of L-T4 and L-T3 fully normalizes T3-dependent metabolic markers and gene expression profiles in Tx rats.

4 October 2016 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SPSarah J. Peterson
Sarah J. Peterson
EMElizabeth A. McAninch
Elizabeth A. McAninch
ABAntonio C. Bianco
Antonio C. Bianco
Context: Levothyroxine (LT4) monotherapy is the standard of care for hypothyroidism. Objective: To determine whether LT4 at doses that normalize the serum TSH is associated with normal markers of thyroid status. Design: Cross-sectional data from the US National Health and Nutrition Examination Survey (2001–2012) was used to evaluate 52 clinical parameters. LT4 users were compared to healthy controls and controls matched for age, sex, race, and serum TSH. Regression was used to evaluate for correlation with T4 and T3 levels. Participants: A total of 9981 participants with normal serum TSH were identified; 469 were LT4-treated. Results: Participants using LT4 had higher serum total and free T4 and lower serum total and free T3 than healthy or matched controls. This translated to approximately 15–20% lower serum T3:T4 ratios in LT4 treatment, as has been shown in other cohorts. In comparison to matched controls, LT4-treated participants had higher body mass index despite report of consuming fewer calories/day/kg; were more likely to be taking beta-blockers, statins, and antidepressants; and reported lower total metabolic equivalents. A serum TSH level below the mean in LT4-treated participants was associated with a higher serum free T4 but similar free and total T3; yet those with lower serum TSH levels exhibited higher serum high-density lipoprotein and lower serum low-density lipoprotein, triglycerides, and C-reactive protein. Age was negatively associated with serum free T3:free T4 ratio in all participants; caloric intake was positively associated in LT4-treated individuals. Conclusions: In a large population study, participants using LT4 exhibited lower serum T3:T4 ratios and differed in 12/52 objective and subjective measures.

1 November 2013 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
ABAntonio C. Bianco
Antonio C. Bianco
EMElizabeth A McAninch
Elizabeth A McAninch

29 September 2015 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
BGBalázs Gereben
Balázs Gereben
EMElizabeth A. McAninch
Elizabeth A. McAninch
MRMiriam O Ribeiro
Miriam O Ribeiro
ABAntonio C. Bianco
Antonio C. Bianco

5 January 2016 in Annals of Internal Medicine
Verified
Journal Article
Closed access
EMElizabeth A. McAninch
Elizabeth A. McAninch
ABAntonio C. Bianco
Antonio C. Bianco
This article describes the evolution of and rationale for changes in the treatment of hypothyroidism over the last century. This article has been corrected. The original version (PDF) is appended to this article as a Supplement. Thyroid hormone replacement has been used for more than a century to treat hypothyroidism. N...